More about
Skin And Muscle Disease
News
July 30, 2024
1 min read
Save
Phase 3 enrollment completed for study evaluating brepocitinib in dermatomyositis
Enrollment in the phase 3 VALOR study evaluating brepocitinib for the treatment of dermatomyositis has been completed, Priovant Therapeutics announced in a press release.